| 000 | 01737 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515071647.0 | ||
| 264 | 0 | _c20070803 | |
| 008 | 200708s 0 0 eng d | ||
| 022 | _a0011-9059 | ||
| 024 | 7 |
_a10.1111/j.1365-4632.2007.03158.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMenter, Alan | |
| 245 | 0 | 0 |
_aTransitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. _h[electronic resource] |
| 260 |
_bInternational journal of dermatology _cJun 2007 |
||
| 300 |
_a637-48 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aDermatologic Agents _xadverse effects |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPUVA Therapy |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHamilton, Tiffani K | |
| 700 | 1 | _aToth, Darryl P | |
| 700 | 1 | _aLeung, Hoi M | |
| 700 | 1 | _aWetherill, Graham | |
| 700 | 1 | _aHennessey, Brian | |
| 700 | 1 | _aGarovoy, Marvin | |
| 700 | 1 | _aKwon, Paul | |
| 700 | 1 | _aPariser, David M | |
| 773 | 0 |
_tInternational journal of dermatology _gvol. 46 _gno. 6 _gp. 637-48 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-4632.2007.03158.x _zAvailable from publisher's website |
| 999 |
_c17089747 _d17089747 |
||